Posting of Annual Report and Notice of AGM
Thalia Therapeutics plc announced that its Annual Report for the year ended 31 December 2025 and the Notice of the Annual General Meeting, which includes proposals for the acquisition of Sanmirna Therapeutics Inc and an associated fundraise, will be posted to shareholders today. The Annual General Meeting is scheduled for 17 July 2026 at 11:00 a.m. at Huckletree Bishopsgate, London.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that its Annual Report for the year ended 31 December 2025 and Notice of the Annual General Meeting, including proposals regarding the acquisition of Sanmirna Therapeutics Inc and associated fundraise, will be posted to shareholders later today, and are available on the Company's website at https://investors.thaliatx.com/aim-rule-26
The Company's Annual General Meeting will be held at 11.00 a.m. on 17 July 2026 at the offices of Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ.
| Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer | Via Thalia Investor Hub https://investors.thaliatx.com/link/eXglky |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke/Josh Ray (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/ Guy McDougall | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Limited Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang | Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.